 |
VasoMedical Products Well Received at ESC 2012 |
September 12, 2012 - WESTBURY, NY VasoMedical, Inc. (“VasoMedical”) (OTC: VASO.QB), a global leader in the manufacture and sale of devices for the non-invasive treatment and management of cardiovascular diseases and a leader in the sale of diagnostic imaging products, reported today that its participation at the 34th European Society of Cardiology (“ESC”) Congress drew significant interest among the many healthcare professionals in attendance. The ESC Congress serves as a forum for the latest research in cardiovascular diseases and is the largest meeting of cardiologists in Europe. This year’s meeting was held in Munich, Germany from August 25th to 28th, and attracted over 25,000 attendees from all over the world.
VasoMedical performed live demonstrations of its LumenairTM EECP® Therapy system in the exhibition hall at the event. Also displayed and demonstrated were VasoMedical’s other technologies, including its unique and easy to use BIOXTM ECG Holter and Ambulatory Blood Pressure Monitoring products, as well as its EZTH series Patient Management products. There was excellent attendance at the booth, and VasoMedical personnel had an opportunity during the four day period to meet with many of its current customers, interested physicians, government officials and other healthcare professionals, distributors and consultants.
"Exhibiting at the ESC Congress is crucial to broadening and enhancing the VasoMedical brand in key global markets," stated Larry Liebman, Vice President of Sales & Marketing. "We are absolutely elated at the level of interest and enthusiasm surrounding our booth and our products." Continuing its global marketing plan, VasoMedical is scheduled to participate and exhibit at many future international meetings, including the following for the rest of 2012:
- November 3-7, 2012: American Heart Association (“AHA”) meeting in Los Angeles, CA
- November 14-17, 2012: Medica, the largest medical equipment show in the world, in Dusseldorf, Germany
- December 5-8, 2012: The Russian Pharma and Medical Device meeting in Moscow, Russia
Please watch for announcements and updates regarding these and future events on the VasoMedical website, and follow the Company on social networks such as Facebook, Twitter, and LinkedIn.
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company operates through three wholly-owned subsidiaries. VasoMedical Solutions manages and coordinates the design, manufacture and sales of EECP® therapy systems, its core product, as well as other medical equipment operations; VasoMedical Global operates the Company’s China-based subsidiaries; and Vaso Diagnostics, d/b/a VasoHealthcare, is the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products. Additional information is available on the Company's website at www.vasoMedical.com.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.